Pavmed Inc. (PAVM) Stock Price & Analysis

Pavmed Inc. (PAVM) fell 9.65% to USD 4.68 as of June 10, 2026 at 05:03 UTC, according to Nexqual real-time market data.

PAVM last closed at USD 5.18; the session ranged USD 4.68–5.41 on volume of 37,628 shares. Market capitalization is $33.50M, with a 52-week range of USD 4.68–28.44 (NCM). Source: Nexqual, June 10, 2026 at 05:03 UTC.

Key Statistics (as of June 10, 2026 at 05:03 UTC)

Technical Analysis (PAVM)

Nexqual's technical model rates PAVM "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:03 UTC.

Analyst Ratings (PAVM)

Wall Street analysts rate PAVM "Strong Buy" based on 2 analysts, with a mean price target of USD 36 (range USD 16–56), per Nexqual as of June 10, 2026 at 05:03 UTC.

Earnings (PAVM)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 05:03 UTC.

Financials & Fundamentals (PAVM)

Source: Nexqual, June 10, 2026 at 05:03 UTC.

Financial Health Score (PAVM)

Nexqual rates Pavmed Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:03 UTC.

Ownership (PAVM)

Source: Nexqual, June 10, 2026 at 05:03 UTC.

Leadership (PAVM)

Pavmed Inc. is led by Lishan Aklog (age 59), Chairman & CEO, per Nexqual as of June 10, 2026 at 05:03 UTC.

Major Backers & Investors (PAVM)

Notable institutional backers of Pavmed Inc. include Two Seas Capital Lp, First Manhattan Co. LLC, Fidelity, according to Nexqual as of June 10, 2026 at 05:03 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 05:03 UTC.

From Pavmed Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)

Key Strengths & Strategy (as disclosed to the SEC)

• This use of EsoGuard together with EsoCheck as a testing system must be cleared or approved by the FDA as an IVD device.   4   Competition   The U.S. market for EAC and pre-cancer (i.e., BE, with or without dysplasia) testing is large, consisting of more than 30 million at-risk individuals over the age of 50.
• Subsequent to December 31, 2025 as of March 27, 2026, Lucid sold 4,161,747 shares through its at-the-market equity facility for net proceeds of approximately $5.3 million, after payment of 3% commissions.   11   Intellectual Property   Our business will depend on proprietary medical device and diagnostic technologies to commercialize.
• Regulation   FDA Regulation   Before and after approval or clearance in the United States, our products are subject to extensive regulation by the FDA under the FDCA and/or the Public Health Service Act, as well as by other regulatory bodies.
• For select technologies shown below, patents have been granted with protection extending to at least the date shown below (although currently pending patent applications, both foreign and domestic, provide protection beyond such date in each instance).       Our policy is to aggressively file patent applications to protect our proprietary technologies including inventions and improvements to inventions.

Partnerships

• Lucid is using the net proceeds from the Lucid September CMPO for working capital and general corporate purposes.   Lucid ATM Facility   On May 30, 2025, Lucid entered into a Controlled Equity Offering Agreement (also "ATM" or "at-the-market" offering) between Lucid and Maxim Group LLC for up to $25 million of its common stock that may be offered and sold from time to time.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:03 UTC. This page is informational and not investment advice.